Cargando…

P1265: TMEM244 GENE EXPRESSION AS A POTENTIAL BLOOD DIAGNOSTIC MARKER THAT CAN DISTINGUISH SÉZARY SYNDROME FROM MYCOSIS FUNGOIDES AND BENIGN ERYTHRODERMA

Detalles Bibliográficos
Autores principales:	Iżykowska, K., Rassek, K., Żurawek, M., Nowicka, K., Joks, M., Olek-Hrab, K., Olszewska, B., Sokołowska–Wojdyło, M., Przybylski, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431203/ http://dx.doi.org/10.1097/01.HS9.0000847924.44181.2d

Ejemplares similares

Hypomethylation of the promoter region drives ectopic expression of TMEM244 in Sézary cells
por: Iżykowska, Katarzyna, et al.
Publicado: (2020)

TMEM244 Is a Long Non-Coding RNA Necessary for CTCL Cell Growth
por: Rassek, Karolina, et al.
Publicado: (2023)

The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome
por: Błażewicz, Izabela, et al.
Publicado: (2021)

Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and Sezary syndrome. Prospective trial (NCT02323659)
por: Chmielowska, Ewa, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

TOX Expression in Mycosis Fungoides and Sezary Syndrome
por: Pileri, Alessandro, et al.
Publicado: (2022)

Nivolumab in two cases of refractory mycosis fungoides erythroderma
por: Chmielowska, Ewa
Publicado: (2021)

Mycosis fungoides: therapeutic difficulties
por: Adamska, Kinga, et al.
Publicado: (2015)

The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome
por: Liu, Zhaorui, et al.
Publicado: (2021)

Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression
por: Dobos, Gabor, et al.
Publicado: (2023)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
por: Lechowicz, Mary Jo, et al.
Publicado: (2014)

Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
por: Vural, Seçil, et al.
Publicado: (2018)

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
por: Maredia, Hasina, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario()()
por: Sanches, José Antonio, et al.
Publicado: (2021)

Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020
por: Ottevanger, R., et al.
Publicado: (2021)

Langerhans cell histiocytosis followed by folliculotropic mycosis fungoides
por: Błażewicz, Izabela, et al.
Publicado: (2017)

Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update()
por: Yamashita, Thamy, et al.
Publicado: (2012)

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
por: Oka, Tomonori, et al.
Publicado: (2019)

A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome
por: Egger, Andjela, et al.
Publicado: (2020)

Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature
por: Ottevanger, R., et al.
Publicado: (2021)

Expression of Thymidine Phosphorylase in Lymph Nodes Involved with Mycosis Fungoides and Sézary Syndrome
por: Nie, Xingcao, et al.
Publicado: (2011)

The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications
por: Pileri, Alessandro, et al.
Publicado: (2021)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management
por: Miyashiro, Denis, et al.
Publicado: (2023)

A Long Journey of Poikilodermatous Erythroderma to Poikilodermatous Mycosis Fungoides: A Case Report
por: Singh, Gautam Kumar, et al.
Publicado: (2022)

Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
por: Prince, H. Miles, et al.
Publicado: (2013)

The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist’s Point of View
por: Giordano, Antonio, et al.
Publicado: (2022)

Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
por: García-Díaz, Nuria, et al.
Publicado: (2021)

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

Itchy Skin: A Challenging Differential Diagnosis Between Mycosis Fungoides and Sézary Syndrome
por: Abreu Rocha, Cláudia, et al.
Publicado: (2023)

Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome
por: Fong, Sophia, et al.
Publicado: (2020)

Photodynamic Therapy with the Silicon Phthalocyanine Pc 4 Induces Apoptosis in Mycosis Fungoides and Sezary Syndrome
por: Lam, Minh, et al.
Publicado: (2010)

Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome
por: ALENEZI, Fawaz, et al.
Publicado: (2021)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
por: Akilov, Oleg E.
Publicado: (2023)

P1532: CLINICAL OUTCOMES OF COVID-19 IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME (MF/SS)
por: Levy, Ilana, et al.
Publicado: (2023)

Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
por: Quadri, Iman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_egg6hea6stkfi4g69rto4ghdi1